Login    Join free Add to favorites    中文
home > news > OGT expands custom NGS cancer panel content and readies
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
OGT expands custom NGS cancer panel content and readies

hits:191     Date:06/13/18
OGT expands custom NGS cancer panel content and readies enhanced software for release
Increased content provides even more flexibility for customisation

Oxford, UK 鈥 12 June 2018. Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its SureSeq myPanel™ NGS Custom Cancer Panel content - now covering 120 fully optimised cancer related genes. The expanded content gives researchers even more freedom to customise their sequencing experiments, enabling focus on regions of interest, saving time and cost. As well as proactive updates, this expansion is in part thanks to OGT鈥檚 responsiveness to customer requests to which the company has created, optimised and validated new content and added it to the portfolio.
 
OGT鈥檚 expert-curated, solid tumour and haematology custom panel content enables users to sequence only the genes and regions relevant to their cancer research - increasing throughput and saving on sequencing reagents. The rigorously pre-optimised panel content facilitates the development of robust NGS assays, whether these are working with challenging sample types, such as FFPE tissue, or on difficult to sequence genes, either due to their high GC content or areas of the genome repetitive by nature, such as internal tandem duplications.
 
OGT鈥檚 unique panel design and advanced hybridisation-based target enrichment delivers unparalleled coverage uniformity. This enables the consistent and confident detection of low frequency variants while simultaneously minimising the need for supplementary fill-in with Sanger sequencing.
 
Researchers can select content from a wide range of available NGS panel content available for solid tumours covering breast cancer, colorectal cancer, glioma, lung cancer, melanoma, ovarian cancer, prostate cancer, and sarcoma. For haematology malignancies, the panel content covers Acute Myeloid Leukaemia (AML), Chronic Lymphocytic Leukaemia (CLL), Chronic Myeloid Leukaemia (CML), Myeloproliferative Neoplasm (MPN), Myelodysplastic Syndromes (MDS) and Myeloid Malignancies.
 
In addition to the expanded content, OGT has completed successful beta trials of the latest version of the SureSeq Interpret™ software, an NGS data analysis pipeline that will be provided free with SureSeq panels. With this software鈥攖he NGS counterpart of OGT鈥檚 popular CytoSure Interpret™ microarray software鈥擮GT aims to support its NGS panel users with an easy-to-use and improved, modular pipeline, database and user interface with multiple deployment options, dynamic filtering and a customisable reporting structure for simple NGS data processing and interpretation.
 
Dave Cook, Senior Product Manager at OGT, commented, 鈥淥ur ever-increasing custom panel content along with NGS-specific software development highlights our commitment to providing customers with the best performing and most convenient NGS products on the market. It also shows how responsive we are as a company and that we have listened to the needs of our customers with respect to the additional capabilities of our data analysis pipeline to accompany our panels 鈥 which we expect to deliver very soon.鈥
 
For more information please visit www.ogt.com/sureseq.  
 
For further information, please contact:
 
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ;
F: +44 (0) 1865 848684
 
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company鈥檚 Cytocell®, CytoSure™ and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease. OGT was acquired by Sysmex Corporation (Sysmex), a Japanese in vitro diagnostic company in June 2017. The acquisition of OGT expands Sysmex鈥檚 life science business and reinforces its initiatives towards personalised medicine.
 
For more information on the Company, please visit our website at www.ogt.com
 
CytoSure™, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. Cytocell: Some products may not be available in your region.
Related News>> more
advertisement

Copyright(C) 2006-2018 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙